NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia....
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...
CLOZAPINE Response in Biotype-1
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a st...
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder....
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia...
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population....
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants age...
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inade...
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine ...
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess advers...
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine...
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 ...
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augment...
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 peop...
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment....
Comparing Antipsychotic Medications in LBD Over Time
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to t...
Study of ALTO-101 in Patients With Schizophrenia
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers an...
Anti-Inflammatory Challenge in Schizophrenia
This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish...
Top Cities for Schizophrenia Clinical Trials
Schizophrenia clinical trials are recruiting across 67 cities. Here are the cities with the most active studies:
About Schizophrenia
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
Clinical trials are advancing new treatments for schizophrenia. Currently, 21 studies are recruiting a combined 6,338 participants across the United States. Research is being conducted by 18 organizations including Neurocrine Biosciences, Reviva Pharmaceuticals, University of Texas Southwestern Medical Center and 15 others.
2026 Schizophrenia Treatment Landscape & Drug Pipeline
Schizophrenia trials in 2026 are focused on mechanisms beyond the dopamine D2 receptor blockade that has defined antipsychotic treatment for 70 years. KarXT (xanomeline-trospium, marketed as Cobenfy) became the first non-dopaminergic antipsychotic, targeting muscarinic receptors instead. It reduces positive symptoms (hallucinations, delusions) without the weight gain, metabolic syndrome, or movement disorders of traditional antipsychotics.
TAAR1 (trace amine-associated receptor 1) agonists represent another breakthrough. Ulotaront (SEP-363856) targets TAAR1 and 5-HT1A receptors, with multiple companies developing competing TAAR1 compounds. These drugs may address both positive and negative symptoms — including social withdrawal, emotional flatness, and cognitive impairment that current antipsychotics largely fail to treat.
Long-acting injectable (LAI) formulations continue advancing, with 3-month and 6-month depot formulations in trials. Extended-release injections dramatically improve treatment adherence — the single biggest predictor of relapse prevention in schizophrenia.
Digital therapeutics and cognitive remediation programs are being tested alongside medications, using structured exercises and smartphone interventions to improve cognitive deficits (memory, attention, processing speed) that medications alone don't address.
Patient considerations: Trials typically require a confirmed diagnosis and stable symptoms for 4+ weeks. Many allow continued background antipsychotic use. Expect regular psychiatric assessments (PANSS, CGI scales) and metabolic monitoring (weight, glucose, lipids). Trials testing new mechanisms may have strict exclusion criteria for treatment-resistant schizophrenia.
Learn More
2026 Schizophrenia Research Landscape
As of March 2026, the schizophrenia clinical trial landscape includes 21 actively recruiting studies across 67 cities in the United States. These studies are collectively seeking 6,338 participants, with an average enrollment target of 302 per study.
Research is being led by 18 different organizations, including Neurocrine Biosciences, Reviva Pharmaceuticals, University of Texas Southwestern Medical Center, Otsuka Pharmaceutical Development & Commercialization, Inc., Intra-Cellular Therapies, Inc., and 13 others. The large number of sponsors reflects significant research interest and investment in schizophrenia treatment advancement.
Geographically, schizophrenia trials are most concentrated in Little Rock, Arkansas (12 trials); Atlanta, Georgia (9 trials); Garden Grove, California (8 trials); New York, New York (7 trials); San Diego, California (6 trials) and 7 other cities.
Featured Schizophrenia Studies
Highlighted recruiting studies for schizophrenia, selected by enrollment size and research scope.
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
CLOZAPINE Response in Biotype-1
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of c...
Frequently Asked Questions About Schizophrenia Clinical Trials
Are there schizophrenia clinical trials near me?
Yes, there are 21 schizophrenia clinical trials currently recruiting across 67+ cities in the United States, including Little Rock, Arkansas; Atlanta, Georgia; Garden Grove, California. Browse the studies above to find one at a location convenient for you.
How do I join a schizophrenia clinical trial?
To join a schizophrenia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are schizophrenia clinical trials free?
Yes, participation in schizophrenia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of schizophrenia treatments are being studied?
Current schizophrenia clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 18 research organizations.
Is it safe to participate in schizophrenia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov